EMERGENT BIOSOLUTIONS SECURES $51.9 MILLION CONTRACT MODIFICATION AWARD FOR CNJ-016® [VACCINIA IMMUNE GLOBULIN INTRAVENOUS (HUMAN)] (VIGIV) AS PART OF U.S. BIODEFENSE PREPAREDNESS EFFORTS

Reuters · 07/08 20:45

Please log in to view news